Sustained release of sphingosine 1-phosphate for therapeutic arteriogenesis and bone tissue engineering.
Sphingosine 1-phosphate (S1P) is a bioactive phospholipid that impacts migration, proliferation, and survival in diverse cell types, including endothelial cells, smooth muscle cells, and osteoblast-like cells. In this study, we investigated the effects of sustained release of S1P on microvascular remodeling and associated bone defect healing in vivo. The murine dorsal skinfold window chamber model was used to evaluate the structural remodeling response of the microvasculature. Our results demonstrated that 1:400 (w/w) loading and subsequent sustained release of S1P from poly(lactic-co-glycolic acid) (PLAGA) significantly enhanced lumenal diameter expansion of arterioles and venules after 3 and 7 days. Incorporation of 5-bromo-2-deoxyuridine (BrdU) at day 7 revealed significant increases in mural cell proliferation in response to S1P delivery. Additionally, three-dimensional (3D) scaffolds loaded with S1P (1:400) were implanted into critical-size rat calvarial defects, and healing of bony defects was assessed by radiograph X-ray, microcomputed tomography (muCT), and histology. Sustained release of S1P significantly increased the formation of new bone after 2 and 6 weeks of healing and histological results suggest increased numbers of blood vessels in the defect site. Taken together, these experiments support the use of S1P delivery for promoting microvessel diameter expansion and improving the healing outcomes of tissue-engineered therapies.
Sefcik
Lauren S
LS
Department of Biomedical Engineering, University of Virginia, Charlottesville, VA 22908, United States.
Petrie Aronin
Caren E
CE
Wieghaus
Kristen A
KA
Botchwey
Edward A
EA
D000818:Animals; D001158:Arteries / Q000254:growth & development*; D001846:Bone Development; D001973:Bromodeoxyuridine; D005455:Fluorescent Antibody Technique; D008246:Lysophospholipids / Q000008:administration & dosage*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D051381:Rats; D013110:Sphingosine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D023822:Tissue Engineering
D008246:Lysophospholipids; C060506:sphingosine 1-phosphate; D001973:Bromodeoxyuridine; D013110:Sphingosine